Open AccessAppropriateness of Biologics in the Management of Crohn’s Disease Using RAND/UCLA Appropriateness Methodology
Author(s) -
Adam V. Weizman,
Geoffrey C. Nguyen,
Cynthia H. Seow,
Laura E. Targownik,
Sanjay K. Murthy,
Karen Boland,
Nooran M Afzal,
Reena Khanna,
Jennifer Jones,
Waqqas Afif,
Smita Halder,
Jason Reinglas,
Sharyle Fowler,
Vivian Huang,
Gilaad G. Kaplan,
Gil Melmed
Publication year - 2018
Publication title -
inflammatory bowel diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.932
H-Index - 146
eISSN - 1536-4844
pISSN - 1078-0998
DOI - 10.1093/ibd/izy333
Subject(s) - crohn's disease , medicine , appropriateness criteria , crohn disease , medical physics , disease , radiology
3 classes of biologics are now available for the treatment of Crohn's disease. The availability of multiple treatment options has led to questions regarding the appropriateness of each agent for a given patient. We aimed to evaluate physician preferences for the use of specific biologic agents in a variety of Crohn's disease management scenarios using the RAND/UCLA Appropriateness Methodology.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom